 approved by the
US Food and Drug Administration for use in patients
with venous disease.
Clinical beneﬁt of hydroxyethylrutosides.
Rationale. Hydroxyethylrutosides are composed by
one or several bioﬂavonoids obtained from hydroxyethylation of rutoside (a combination of ﬂavonol quercetin
and disaccharide rutinose). Hydroxyrutoside is a potent
inhibitor of in